Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
177Lu-NARI-FAPI-1.21 is a radiolabeled, long-acting fibroblast activation protein (FAP) inhibitor (FAPI) developed by the National Atomic Research Institute (NARI) in Taiwan [EP-0094]. The drug consists of the FAPI precursor NARI-FAPI-1.21 (supplied by Kelowna International Scientific) radiolabeled with Lutetium-177 (177Lu) [EP-0094]. It is designed to target FAP, which is highly overexpressed on cancer-associated fibroblasts (CAFs) in the tumor microenvironment of various solid tumors [EP-0094]. Preclinical studies in HEK-293-FAP solid tumor models have demonstrated that 177Lu-NARI-FAPI-1.21 has favorable cell-binding properties, prolonged in vivo circulation, and enhanced long-term accumulation at tumor sites, making it a promising candidate for targeted radionuclide therapy and SPECT/CT imaging [EP-0094].
| Market | Status | Year |
|---|---|---|
| United States | Not approved | — |
| European Union | Not approved | — |
| China | Not approved | — |
| Japan | Not approved | — |
Approved indications and other markets are in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 177Lu-NARI-FAPI-1.21.
Work on 177Lu-NARI-FAPI-1.21? Claim this page to correct or add information. Claim this page